Sanofi Q3 2026 non-IFRS business EPS rises 22% to €3.55
SNY•Sanofi’s Q3 2026 non-IFRS business earnings per share rose 22% to €3.55, while net sales climbed 16% to €14.44 billion.
SNY•SNY•SNY•Sanofi’s Q3 2026 non-IFRS business earnings per share rose 22% to €3.55, while net sales climbed 16% to €14.44 billion.
Sanofi reported that Q3 2026 non-IFRS business earnings per share rose 22% to €3.55 and net sales climbed 16% to €14.44 billion. The company also expanded its Regeneron alliance in immunology and partnered with Cheplapharm to simplify its legacy-medicine portfolio.
